Gain Therapeutics: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $8

HC Wainwright & Co. reiterates 'Buy' rating on Gain Therapeutics(GANX).

The target price is unchanged and still at 8 .

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-12-19	HC Wainwright & Co.	Reiterates	Buy	Buy	$8	$8

[Recent Earning Results] Gain Therapeutics posted the Q3 of its 2025 financial results on 11/12/2025, reporting net income of USD -15.62 million in the first three quarters, narrowing 6.13% from USD -16.64 million year over year.

[Company Profile] Gain Therapeutics, Inc., incorporated in Delaware on June 26, 2020. The company is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.